Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

NCT02102594 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.

NCT NCT02102594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02102594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
Lead sponsor
Charite University, Berlin, Germany
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2014
Completion date
August 30, 2019
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus